期刊
KIDNEY INTERNATIONAL
卷 78, 期 -, 页码 S33-S37出版社
ELSEVIER SCIENCE INC
DOI: 10.1038/ki.2010.420
关键词
Affymetrix; chronic rejection; GeneChip; kidney transplantation; microarray
资金
- Pfizer (Wyeth)
- Genentech
- Novartis
- Wyeth
- Roche
- Jansen Cilag
- Astellas
- NHMRC of Australia
- NIH
- JDRF
Chronic allograft injury (CAI) is common after kidney transplantation in which immunological (e.g., acute and chronic cellular and antibody-mediated rejection) and nonimmunological factors (e.g., donor-related factors, ischemia-reperfusion injury, polyoma virus, hypertension, and calcineurin inhibitor nephrotoxicity) have a role. Despite the new Banff pathological classification, histopathological diagnosis is still far from being the 'gold standard' to understand the exact mechanisms in the development of CAI, which may lead to appropriate treatment. Microarray is a powerful technology that detects thousands of genes simultaneously and might be an important tool in elucidating patterns for mechanism, diagnosis, prognosis, and treatment of complex, multifactorial diseases, such as CAI. In this review, we discuss the studies that applied microarray technology in kidney transplant patients with CAI.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据